Cargando…

Dynamic disease manifestations among individuals infected with SARS-CoV-2 Omicron variant

Detalles Bibliográficos
Autores principales:	Wang, Peiqin, Feng, Xinwei, Shi, Zhiwen, Jiang, Zimao, Wang, Luping, Gao, Xin, Qi, Hui, Chen, Min, Wang, Jian, Xie, Weifen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684227/ https://www.ncbi.nlm.nih.gov/pubmed/37434269 http://dx.doi.org/10.1097/CM9.0000000000002726

Ejemplares similares

Plasma Neutralization of the SARS-CoV-2 Omicron Variant
por: Schmidt, Fabian, et al.
Publicado: (2021)

Increased immune escape of the new SARS-CoV-2 variant of concern Omicron
por: Hu, Jie, et al.
Publicado: (2022)

Structures of ACE2–SIT1 recognized by Omicron variants of SARS-CoV-2
por: Shen, Yaping, et al.
Publicado: (2022)

T cell epitopes in SARS-CoV-2 proteins are substantially conserved in the Omicron variant
por: Choi, Seong Jin, et al.
Publicado: (2022)

Vaccine booster efficiently inhibits entry of SARS-CoV-2 omicron variant
por: Zhang, Wei, et al.
Publicado: (2022)

Protection against the Omicron Variant from Previous SARS-CoV-2 Infection
por: Altarawneh, Heba N., et al.
Publicado: (2022)

Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants
por: Yu, Jingyou, et al.
Publicado: (2022)

Sotrovimab drives SARS-CoV-2 omicron variant evolution in immunocompromised patients
por: Destras, Grégory, et al.
Publicado: (2022)

Liver injury caused by SARS-CoV-2 Delta and Omicron-variant in Taiwan
por: Jang, Tyng-Yuan
Publicado: (2022)

Virological characteristics of the SARS-CoV-2 omicron XBB.1.16 variant
por: Yamasoba, Daichi, et al.
Publicado: (2023)

Serum neutralisation of the SARS-CoV-2 omicron sublineage BA.2
por: Chen, Lin-Lei, et al.
Publicado: (2022)

SARS-CoV-2 Omicron variant virus isolates are highly sensitive to interferon treatment
por: Bojkova, Denisa, et al.
Publicado: (2022)

SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons
por: Rössler, Annika, et al.
Publicado: (2022)

Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2
por: Antonelli, Michela, et al.
Publicado: (2022)

SARS-CoV-2 variant omicron XBB.1.5: challenges and prospects – correspondence
por: Channabasappa, Nikhil K., et al.
Publicado: (2023)

SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination
por: Pajon, Rolando, et al.
Publicado: (2022)

Reduced sensitivity of SARS-CoV-2 Omicron variant to antibody neutralization elicited by booster vaccination
por: Yu, Xiaoqi, et al.
Publicado: (2022)

Proteomic characterization of Omicron SARS-CoV-2 host response
por: Bao, Jianfeng, et al.
Publicado: (2022)

Outcome of infection with omicron SARS‐CoV‐2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report
por: Blennow, Ola, et al.
Publicado: (2022)

Enhanced transmissibility, infectivity, and immune resistance of the SARS-CoV-2 omicron XBB.1.5 variant
por: Uriu, Keiya, et al.
Publicado: (2023)

Substantial Neutralization Escape by SARS-CoV-2 Omicron Variants BQ.1.1 and XBB.1
por: Miller, Jessica, et al.
Publicado: (2023)

More data needed on efficacy and safety of monovalent vaccines against SARS-CoV-2 omicron variants
por: Monach, Paul A, et al.
Publicado: (2023)

Evolving spike mutations in SARS-CoV-2 Omicron variants facilitate evasion from breakthrough infection-acquired antibodies
por: Chen, Shiqi, et al.
Publicado: (2023)

Resistance of SARS-CoV-2 omicron subvariant BA.4.6 to antibody neutralisation
por: Wang, Qian, et al.
Publicado: (2022)

Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum
por: Dejnirattisai, Wanwisa, et al.
Publicado: (2022)

Replicative capacity of SARS-CoV-2 omicron variants BA.5 and BQ.1.1 at elevated temperatures
por: Muramoto, Yukiko, et al.
Publicado: (2023)

Omicron SARS-CoV-2 Neutralization from Inactivated and ZF2001 Vaccines
por: Zhao, Xin, et al.
Publicado: (2022)

Impact of SARS-CoV-2 envelope protein mutations on the pathogenicity of Omicron XBB
por: Wang, Yi, et al.
Publicado: (2023)

Severity of SARS-CoV-2 Omicron XBB subvariants in Singapore
por: Pung, Rachael, et al.
Publicado: (2023)

Olverembatinib inhibits SARS‐CoV‐2‐Omicron variant‐mediated cytokine release in human peripheral blood mononuclear cells
por: Chan, Marina, et al.
Publicado: (2022)

Humoral and cellular immunity to SARS-CoV-2 Ancestral and Omicron BA.5 variants following vaccination in myelofibrosis patients
por: Alcheikh, Ahmad, et al.
Publicado: (2023)

A SARS-CoV-2 omicron (B.1.1.529) variant outbreak in a primary school in Geneva, Switzerland
por: Lorthe, Elsa, et al.
Publicado: (2022)

The SARS‐CoV‐2 Omicron (B.1.1.529) variant and the re‐emergence of COVID‐19 in Europe: An alarm for Bangladesh
por: Islam, Md. Rabiul
Publicado: (2022)

Ceftazidime exhibits a broad inhibition to the infection of SARS-CoV-2 prototype and Omicron variant in vitro by blocking spike protein-ACE2 interaction
por: Zheng, Yun-zhe, et al.
Publicado: (2023)

Antigenic mapping of emerging SARS-CoV-2 omicron variants BM.1.1.1, BQ.1.1, and XBB.1
por: Mykytyn, Anna Z, et al.
Publicado: (2023)

Characteristics and implications of Omicron variant associated digestive system infections – Correspondence
por: Shi, Yunjie, et al.
Publicado: (2022)

SARS‐CoV‐2 Omicron emergence urges for reinforced One‐Health surveillance
por: Montagutelli, Xavier, et al.
Publicado: (2022)

Neutralization Profile after Recovery from SARS-CoV-2 Omicron Infection
por: Rössler, Annika, et al.
Publicado: (2022)

Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies
por: Yamasoba, Daichi, et al.
Publicado: (2022)

Neutralisation sensitivity of the SARS-CoV-2 omicron BA.2.75 sublineage
por: Gruell, Henning, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fflg7t2ilolutq3mop3s62315f